ReviewCurrent cardiology reports2026
Interrelationships Between Key Cardiovascular Risk Factors, Chronic Kidney Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease.
Review in Current cardiology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewFive modifiable risk factors (RFs) - systolic blood pressure (SBP), body mass index (BMI), diabetes, non-high-density lipoprotein cholesterol (non-HDL-C), and smoking - were proposed as major determinants of the global burden of cardiovascular disease (CVD). This narrative review considers the interconnections among these RFs and their combined influence on disease development, progression, and longevity. We also consider the relationship between these factors and chronic kidney disease (CKD) and metabolic dysfunction-associated steatotic liver disease (MASLD). RECENT
findingsOver the past three decades, the global prevalence and burden of CVD, CKD, and MASLD has risen substantially. These chronic conditions are leading causes of reduced life expectancy and increased disability-adjusted life years (DALYs). They share common underlying mechanisms, particularly insulin resistance and chronic inflammation, and frequently coexist, with each condition accelerating the progression and complications of the others. Evidence from studies and meta-analyses demonstrates that the five traditional RFs significantly contribute to disease onset and progression, while effective risk-factor management can delay disease progression and improve both quality of life and survival. Lifestyle interventions and emerging pharmacological therapies can favorably modify these RFs and reduce the overall burden of CVD, CKD, and MASLD. An integrated approach to managing metabolic dysfunction is essential, although it remains challenging, as improvement in one condition may adversely affect another. RFs should not just be considered individually.
Indexed as
Identifiers
41973270What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.